LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to pr...

Full description

Bibliographic Details
Main Authors: Takahiro Yamazaki, Erik Wennerberg, Michal Hensler, Aitziber Buqué, Jeffrey Kraynak, Jitka Fucikova, Xi Kathy Zhou, Baldur Sveinbjørnsson, Øystein Rekdal, Sandra Demaria, Lorenzo Galluzzi
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
cdc1s
ctla4
immune checkpoint inhibitors
mpa/dmba-driven mammary carcinomas
pd-1
ts/a cells
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1962592

Internet

http://dx.doi.org/10.1080/2162402X.2021.1962592

Similar Items